肝内胆管癌患者化疗后快速进展或长期生存的分子特征
研究比较了晚期肝内胆管癌化疗后快速进展者(生存<6个月)与长期生存者(生存>23个月)的诊断活检组织转录组特征,发现治疗前转录组谱可区分两类患者,该特征源于肿瘤-髓系细胞动态改变导致的免疫耐受,且与肝内胆管癌及结直肠癌肝转移的临床结局相关,但在肝外胆管癌及匹配的原发肠道肿瘤中不相关。
要点
- 治疗前转录组谱可区分肝内胆管癌化疗后快速进展者与长期生存者。
- 该特征源于肿瘤-髓系细胞动态改变,提示肿瘤诱导的免疫耐受与化疗反应差相关。
- 该特征与肝内胆管癌及结直肠癌肝转移的临床结局相关,但与肝外胆管癌及匹配的原发肠道肿瘤不相关。
核心结论
- RPLS特征可能成为肝内胆管癌化疗结局的新指标,需进一步开发与验证以制定精准化疗策略。
研究设计与样本
- 研究纳入基线特征可比的晚期肝内胆管癌患者,按化疗后生存期分为快速进展者(生存<6个月)与长期生存者(生存>23个月)。
- 对诊断活检组织进行数字病理学表征,并对整体及地理空间宏切割组织区域进行全转录组谱分析。
- 使用靶向数字空间谱分析(GeoMx)对肿瘤浸润髓系细胞进行空间转录组学分析。
- 在多个切除肿瘤队列中评估转录组特征,并利用体外细胞系、体内小鼠模型及单细胞RNA测序数据进行表征。
主要发现
- 治疗前转录组谱可区分化疗后将成为快速进展者或长期生存者的患者。
- 该特征起源于肿瘤-髓系细胞动态改变,提示肿瘤诱导的免疫耐受与化疗反应差相关。
- RPLS转录组特征与肝内胆管癌临床结局相关,但在肝外胆管癌中不相关。
- RPLS转录组特征与结直肠癌肝转移临床结局相关,但在匹配的原发肠道肿瘤中不相关。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Cytotoxic agents are the cornerstone of treatment for patients with advanced intrahepatic cholangiocarcinoma (iCCA), despite heterogeneous benefit. We hypothesised that the pretreatment molecular profiles of diagnostic biopsies can predict patient benefit from chemotherapy and define molecular bases of innate chemoresistance. DESIGN: We identified a cohort of advanced iCCA patients with comparable baseline characteristics who diverged as extreme outliers on chemotherapy (survival <6 m in rapid progressors, RP; survival >23 m in long survivors, LS). Diagnostic biopsies were characterised by digital pathology, then subjected to whole-transcriptome profiling of bulk and geospatially macrodissected tissue regions. Spatial transcriptomics of tumour-infiltrating myeloid cells was performed using targeted digital spatial profiling (GeoMx). Transcriptome signatures were evaluated in multiple cohorts of resected cancers. Signatures were also characterised using in vitro cell lines, in vivo mouse models and single cell RNA-sequencing data. RESULTS: Pretreatment transcriptome profiles differentiated patients who would become RPs or LSs on chemotherapy. Biologically, this signature originated from altered tumour-myeloid dynamics, implicating tumour-induced immune tolerogenicity with poor response to chemotherapy. The central role of the liver microenviroment was confrmed by the association of the RPLS transcriptome signature with clinical outcome in iCCA but not extrahepatic CCA, and in liver metastasis from colorectal cancer, but not in the matched primary bowel tumours. CONCLUSIONS: The RPLS signature could be a novel metric of chemotherapy outcome in iCCA. Further development and validation of this transcriptomic signature is warranted to develop precision chemotherapy strategies in these settings.
引用
- O'Rourke CJ, Salati M, Rae C, et al. Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy. Gut. 2024. PMID: 37758326. doi:10.1136/gutjnl-2023-330748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。